| Literature DB >> 25996355 |
Diane Uzarski1, James Burke2, Barbara Turner3, James Vroom3, Nancy Short3.
Abstract
Researcher-initiated biobanks based at academic institutions contribute valuable biomarker and translational research advances to medicine. With many legacy banks once supported by federal funding, reductions in fiscal support threaten the future of existing and new biobanks. When the Brain Bank at Duke University's Bryan Alzheimer's Disease Center (ADRC) faced a funding crisis, a collaborative, multidisciplinary team embarked on a 2-year biobank sustainability project utilizing a comprehensive business strategy, dedicated project management, and a systems approach involving many Duke University entities. By synthesizing and applying existing knowledge, Duke Translational Medicine Institute created and launched a business model that can be adjusted and applied to legacy and start-up academic biobanks. This model provides a path to identify new funding mechanisms, while also emphasizing improved communication, business development, and a focus on collaborating with industry to improve access to biospecimens. Benchmarks for short-term Brain Bank stabilization have been successfully attained, and the evaluation of long-term sustainability metrics is ongoing.Entities:
Keywords: biobanking; biomarker research; sustainability
Mesh:
Substances:
Year: 2015 PMID: 25996355 PMCID: PMC4626329 DOI: 10.1111/cts.12287
Source DB: PubMed Journal: Clin Transl Sci ISSN: 1752-8054 Impact factor: 4.689